Aethlon Medical (NASDAQ:AEMD – Get Free Report) and Centene (NYSE:CNC – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Aethlon Medical and Centene, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aethlon Medical | 0 | 1 | 0 | 0 | 2.00 |
Centene | 1 | 13 | 4 | 0 | 2.17 |
Aethlon Medical currently has a consensus price target of $56.00, indicating a potential upside of 3,900.00%. Centene has a consensus price target of $52.50, indicating a potential upside of 78.59%. Given Aethlon Medical’s higher possible upside, equities research analysts plainly believe Aethlon Medical is more favorable than Centene.
Volatility & Risk
Valuation & Earnings
This table compares Aethlon Medical and Centene”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aethlon Medical | N/A | N/A | -$13.39 million | ($12.64) | -0.11 |
Centene | $169.28 billion | 0.09 | $3.31 billion | $6.71 | 4.38 |
Centene has higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than Centene, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Aethlon Medical and Centene’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Aethlon Medical | N/A | -221.38% | -156.83% |
Centene | 2.04% | 14.56% | 4.75% |
Institutional & Insider Ownership
2.0% of Aethlon Medical shares are held by institutional investors. Comparatively, 93.6% of Centene shares are held by institutional investors. 1.2% of Aethlon Medical shares are held by company insiders. Comparatively, 0.4% of Centene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Centene beats Aethlon Medical on 10 of the 13 factors compared between the two stocks.
About Aethlon Medical
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.
About Centene
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.